Patents
Literature
Hiro is an intelligent assistant for R&D personnel, combined with Patent DNA, to facilitate innovative research.
Hiro

44 results about "Muscle disorder" patented technology

Impairment of health or a condition of abnormal functioning of the muscle.

Phycotoxins and Uses Thereof

Pharmaceutical compositions comprising tricyclic 3,4-propinoperhydropurines and uses thereof for blocking neuronal transmission which are useful in treating anal fissure and other wounds and muscle disorders are provided. Also provided are methods of treating wounds and muscle disorders by administering the composition of the invention to a muscle or in the vicinity of a muscle either topically or by injection.
Owner:PHYTOTOX LTD

Electrical Impedance Myography

InactiveUS20100292603A1Facilitate diagnosis and treatmentImprove assessmentElectromyographySensorsElectromyographyElectrical impedance
Electrical impedance myography (EIM) can be used for the assessment and diagnosis of muscular disorders. EIM includes applying an electrical signal to a region of tissue and measuring a resulting signal. A characteristic of the region of tissue is determined based on the measurement. Performing EIM at different frequencies and / or different angular orientations with respect to a muscle can aid in the assessment and diagnosis. Devices are described that facilitate assessment and diagnosis using EIM.
Owner:NORTHEASTERN UNIV +1

System and method for detecting an involuntary muscle movement disorder

Methods and systems are directed to evaluating a pathological condition and involve acquiring muscle movement signals, such as electromyogram (EMG) or accelerometer signals, and detecting the presence of the pathological condition. Methods and systems also provide for detecting sleep-related involuntary muscle disorders and non sleep-related involuntary muscle disorders using muscle movement signals. Drug therapy, transcutaneous electric nerve stimulation therapy, or other therapy may be delivered to treat a detected or diagnosed involuntary muscle disorder.
Owner:CARDIAC PACEMAKERS INC

Detecting device and detecting equipment for swallowing muscle disorders

The invention provides a detecting device and detecting equipment for swallowing muscle disorders. The detecting device is characterized by comprising a collecting module, a processing module and an analyzing and judging module; the collecting module is used for acquiring continuous surface electromyogram signals generated by swallowing muscles under different swallowing actions; the processing module is used for processing the surface electromyogram signals collected by the collecting module to acquire high-density dynamic potential graphs; the analyzing and judging module is used for comparing the high-density dynamic potential graphs acquired by processing of the processing module with a standard high-density dynamic potential graph and judging health conditions of swallowing muscle groups so as to evaluate and diagnose swallowing functions. The detecting equipment comprises the detecting device. A multi-channel electromyogram collection system is used for collecting high-density electromyogram signals of the swallowing muscle groups, so that evaluation and diagnosis of the swallowing functions can be realized, and muscles causing swallowing disorders can be positioned.
Owner:SHENZHEN INST OF ADVANCED TECH CHINESE ACAD OF SCI

Compositions and methods of treatment using nicotinamide mononucleotide

Various methods and compositions for treating age-associated conditions and other medical conditions, such as muscle diseases, type 2 diabetes, and / or obesity are described. Methods of enhancing cellular uptake of NMN and stimulating NAD+ production are further described. Various mammalian cells and mammalian cell lines are described including those comprising a cDNA encoding a Slcl2a8 protein. Gene therapy vectors comprising a nucleic acid encoding Slcl2a8 and non- human animals comprising an inactivating mutation in a Slcl2a8 gene are also disclosed. Also described are methods for screeninga candidate compound to identify compounds that promote NMN transport.
Owner:UNIV OF WASHINGTON

Pharmaceutical composition containing mitochondria

The present invention relates to a pharmaceutical composition containing mitochondria and, more specifically, to a pharmaceutical composition for preventing or treating muscle diseases or ischemic diseases, containing mitochondria as active ingredients. The pharmaceutical composition of the present invention contains heterologous mitochondria or cells comprising heterologous mitochondria, therebyenabling the mitochondrial activity of cells to which the same is administered to improve. Therefore, the pharmaceutical composition according to the present invention can be useful in the fundamentalprevention or treatment of muscle diseases or ischemic diseases, which occur in relationship with the deterioration of mitochondrial function.
Owner:PAEAN BIOTECH

High throughput and functional screening method for muscle related disorders and biological processes

ActiveUS20180356400A1Compound screeningApoptosis detectionMuscle metabolismMuscle contraction
The invention relates to a method for high throughput screening compounds by using a plurality of automated cell based assays assessing skeletal muscle cells contractility, morphology, and metabolism, in order to predict the efficacy of said compound on a panel of applications linked with muscle physiological and pathophysiological processes, comprising: (i) providing an in vitro culture of myotubes, wherein the in vitro myotubes culture is obtained by the following method: providing a cell culture device allowing the culture of myoblasts or myotubes, depositing said cells from a human donor or human group of donors, in good health or affected by a muscle related disorder, from primary cells, a cell line, an isogenic cell line or differentiated stem cells recapitulating a muscle disorder, on said culture device by using a method allowing the spatial control of cell culture, culturing said cells during a determined incubation time so as to promote a spatially controlled myotube culture; (ii) adding at least one compound to said culture; (iii) after a determined incubation time of the myotubes with said compound, carrying out structural and / or functional readouts of the myotubes to determine the effect of said compound on the myotubes; and (iv) based on said determined effect, predicting the ability of said compound to improve or alter healthy muscle features, or to treat, rescue, or cure muscle disorders, said features or said disorders being linked with muscle contraction, muscle morphology or muscle metabolism.
Owner:CYTOO

Ornithine- or aspartate-containing compositions and the uses thereof

Methods and compositions comprising ornithine and / or aspartate that are useful for lowering one or more hyperlipidemic risk factor levels are described. More specifically, compositions comprising ornithine and / or aspartate that are useful for lowering lipid and / or lipoprotein levels, such as triglyceride, cholesterol and LDL levels, in the bloodstream in a subject are described. Methods of using compositions comprising ornithine and / or aspartate for ameliorating the side-effect induced by a therapeutic agent (e.g., statin) or a condition that is associated with an elevation of CPK (e.g., rhabdomyolysis or myopathy) are also described.
Owner:WUHAN QR PHARMA CO LTD

Antineoplastic medicament and adenovirus composite preparations and uses thereof

The present invention belongs to the biological field and the medical field, which relates to an adenovirus composite preparation for a new genetic therapy as well as the application and the application method. The present invention demonstrates that when the adenovirus is taken as a gene delivery vector, the combined use of adenovirus with a certain dose of antitumor drug can dramatically enhance the foreign gene expression of the adenovirus and significantly prolong the period of the foreign gene expression, and the therapy effect of the gene is improved. The composite preparation and the application method of the present invention can be applied as a guide of the genetic therapy of the malignant tumor, the eye disease, the genetic disease, the cardiovascular disease and the neuromuscular disorder, etc.
Owner:上海交通大学附属第一人民医院

System and method for using platelet biomarkers for diagnosis and treatment of neuro-psychiatric conditions

The invention concerns in-vitro evaluation of intracellular biomarkers by doing blood testing. Concentrations of neurotransmitters in the platelet cells are utilized to identify chemical imbalance in the central nervous system. In one embodiment of the invention, testing data is analyzed by proprietary software algorithms by physicians and related health care professionals to diagnose and treat sufferers of chemical imbalance objectively. In another embodiment of the invention the testing and software predetermines risks of developing various neuropsychiatric conditions, like depression, Parkinson's, Alzheimer's, bipolar disorder, ADD / ADHD, autism, asperger's syndrome, OCD and other anxiety disorders, muscle disorders, etc.
Owner:JASUJA SANJAY

Composition for improvement of muscle function containing 3,5-dicaffeoylquinic acid or chrysanthemum extract

The present invention relates to a composition for preventing or treating a muscle disorder, which includes a chrysanthemum extract or 3,5-dicaffeoylquinic acid as an active ingredient, and specifically, it may be used to reduce mRNA expression of atrogin-1 and MuRF1, which are main biomarkers involved in muscle protein degradation and increase mRNA expression of the mTOR protein, which is a main biomarker involved in muscle protein formation, and myogenin and MyoD, which are biomarkers related to muscle differentiation, thereby reducing muscle loss, and thus the chrysanthemum extract or 3,5-dicaffeoylquinic acid can be used in prevention and treatment of a muscle disorder, or improvement in muscle function. In addition, the chrysanthemum extract or 3,5-dicaffeoylquinic acid increases the activity of SIRT1 and PGC-1α, which are the main biomarkers involved in exercise performance, thereby excellently enhancing exercise performance. In addition, the present invention is a natural substance and may be safely used without a side effect, and therefore may be used as a medication, food or a cosmetic.
Owner:COSMAX NBT INC +1

Mao-b inhibitors and rehabilitation

InactiveUS20170273968A1Facilitating muscle re-educationMaintains and increases range of motionNervous disorderMuscular disorderDiseasePhysical medicine and rehabilitation
Methods of rehabilitation of neurological disorders, including neurological deficits associated with neurotraumas, such as stroke and traumatic brain injury, and with muscle disorders, that includes administering to a subject a MAO-B inhibitor.
Owner:DART NEUROSCIENCE CAYMAN LTD

Pro-drugs of nsaias with very high skin and membranes penetration rates and their new medicinal uses

ActiveUS20100172960A1Low pharmacologic effectToxic burdenOrganic active ingredientsBiocideDiseaseSolubility
The novel positively charged pro-drugs of NSAIAs in the general formulas (1, 2a, 2b, 2c, or 2d) “Structure 1, 2a, 2b, 2c, or 2d” were designed and synthesized. The compounds of the general formulas (1, 2a, 2b, 2c, or 2d) “Structure 1, 2a, 2b, 2c, or 2d” indicated above can be prepared from metal salts, organic base salts, or immobilized base salts of NSAIAs with suitable halide compounds. The positively charged amino groups in the pro-drugs in this invention largely increase the solubility of the drugs in water and will bond to the negative charge on the phosphate head group of membrane. Thus, the local concentration of the outside of the membrane or skin will be very high and will facilitate the passage of these pro-drugs from a region of high concentration to a region of low concentration. This bonding will disturb the membrane a little bit and may make some room for the lipophilic portion of the pro-drug. When the molecules of membrane move, the membrane may “crack” a little bit due to the bonding of the pro-drug. This will let the pro-drug insert into the membrane. At pH 7.4, only about 99% of the amino group is protonated. When the amino group is not protonated, the bonding between the amino group of the pro-drug and the phosphate head group of the membrane will disassociate, and the pro-drug will enter the membrane completely. When the amino group of the pro-drug flips to the other side of the membrane and thus becomes protonated, then the pro-drug is pulled into the cytosol, a semi-liquid concentrated aqueous solution or suspension. These pro-drugs can be used for treating and preventing diabetes (type I or / and type II), abnormal blood glucose and lipid levels, stroke, heart attack, and other heart and vascular diseases Alzheimer's diseases, Parkinson's diseases and other neurodegenerative diseases, psoriasis, discoid lupus erythematosus, systemic lupus erythematosus (SLE), autoimmune hepatitis, multiple sclerosis (MS), and other autoimmune diseases, amyotrophic lateral sclerosis (ALS), oculopharyngeal muscular dystrophy (OPMD), and other muscle disorders, inflamed hemorrhoids, cryptitis, other inflammatory conditions of the anorectum, and pruritus ani, prostatitis, prostatocystitis, varicose veins, autoimmune liver inflammation, autoimmune kidney inflammation, vein inflammation and other inflammations, skin cancers, breast cancer, colon-rectum cancer, oral cancer, and other cancers, scars, abnormal vascular skin lesions, birthmarks, moles (nevi), skin tags, aging spots (liver spots), and other skin disorders. These pro-drugs can be administered transdermally without the help of skin penetration enhancers.
Owner:TECHFIELDS BIOCHEM CO LTD

Cerebrovascular therapeutic instrument

The invention discloses a cerebrovascular therapeutic instrument, which comprises a host and an electrode, the electrode comprises an electrode piece and a ball-type electroencephalogram electrode, and the electrode piece and the ball-type electroencephalogram electrode are connected to the host, the ball-type electroencephalogram electrode comprises a liquid storage bottle and a conductive head,wherein the liquid storage bottle is provided with a conductive liquid and a conductive wire, the conductive wire is connected to the conductive head and the host, and the conductive head is rolled and detachably arranged at a bottleneck of the liquid storage bottle. The electrostimulation current emitted by the cerebrovascular therapeutic instrument disclosed by the invention is the one-way pulsecurrent, which can pass through a brain skull with a relatively low conductivity as well as directly and effectively stimulates the cranial nerve and the cerebral blood vessel, and the cerebrovascular therapeutic instrument provides a new prevention and treatment means for cerebrovascular diseases such as cerebral infarction, dementia, cerebral hemorrhage, headache, encephalitis, dizziness, sequelae of brain trauma, muscle disorders and mental retardation.
Owner:太原市怀诚医疗器械有限公司

Kit for detecting mutations causing genetic disorders

The present invention relates to a kit based on ARMS-PCR / AS-PCR in a single tube reaction for detecting mutations causing genetic disorders such as hemoglobinopathy and muscle disorders using untreated human dried blood spots.
Owner:COUNCIL OF SCI & IND RES

Composition for promoting myogenesis, containing processed ginseng extract

The present invention relates to a composition for promoting myogenesis, containing, as an active ingredient, a processed ginseng extract in which a trace amount of a ginsenoside ingredient is increased. It has been ascertained that the processed ginseng extract promotes the differentiation of myoblasts into muscle and inhibits muscle atrophy caused by myostatin, which is a myogenesis inhibitory factor, and thus it is expected that a composition for preventing or treating muscle disorder-related diseases, having excellent effects, can be developed.
Owner:GREEN CROSS HEALTH SCI

Applications of an immune system-released activating agent (ISRAA)

The present invention relates to applications of an immune system-released activating agent (ISRAA) polypeptide, which is induced by a nervous stimulus and which has been found to mediate the transmission of signals between the immune system and the nervous system following an immune challenge. The ISRAA polypeptide is for use in a method of treatment of patients with immunodeficiency, immunosuppression or autoimmune disease; cancer; neurologic diseases and disorders; or muscular diseases and disorders.
Owner:ARABIAN GULF UNIVERSITY

Cortex eucommiae and herba dendrobii medicinal liquor and preparation method thereof

The invention discloses cortex eucommiae and herba dendrobii medicinal liquor and a preparation method thereof, and belongs to the technical field of traditional Chinese medicine. The cortex eucommiaeand herba dendrobii medicinal liquor is prepared from the following raw materials: 110g-130g of cortex eucommiae, 80g-90g of herba dendrobii, 12g-18g of twotooth achyranthes root, 12g-18g of radix rehmanniae preparata, 80g-100g of radix salviae miltiorrhizae, 55g-65g of cortex cinnamomi, 12g-18g of radix flemingiaes, 12g-18g of radix millettiae speciosae, 12g-18g of polygala fallax hemsl, 12g-18gof convolvulaceae ipomoea cairica and 3,880g-4,200ml of rice wine. The cortex eucommiae and herba dendrobii medicinal liquor is formulated from a variety of traditional Chinese medicine and has reasonable compositions and proper compatibility, and effective ingredients of each component can be fully released; and the cortex eucommiae and herba dendrobii medicinal liquor has the effects of replenishing kidney and strengthening bones and muscles, and can effectively treat waist and foot aching and tired, walking weakness, bones-and-muscle disorder and other diseases.
Owner:广西金秀瑶族自治县瑶皇酒坊有限公司

High throughput and functional screening method for muscle related disorders and biological processes

ActiveUS11061017B2Compound screeningApoptosis detectionDiseaseMuscle metabolism
The invention relates to a method for high throughput screening compounds by using a plurality of automated cell based assays assessing skeletal muscle cells contractility, morphology, and metabolism, in order to predict the efficacy of said compound on a panel of applications linked with muscle physiological and pathophysiological processes, comprising: (i) providing an in vitro culture of myotubes, wherein the in vitro myotubes culture is obtained by the following method: providing a cell culture device allowing the culture of myoblasts or myotubes, depositing said cells from a human donor or human group of donors, in good health or affected by a muscle related disorder, from primary cells, a cell line, an isogenic cell line or differentiated stem cells recapitulating a muscle disorder, on said culture device by using a method allowing the spatial control of cell culture, culturing said cells during a determined incubation time so as to promote a spatially controlled myotube culture; (ii) adding at least one compound to said culture; (iii) after a determined incubation time of the myotubes with said compound, carrying out structural and / or functional readouts of the myotubes to determine the effect of said compound on the myotubes; and (iv) based on said determined effect, predicting the ability of said compound to improve or alter healthy muscle features, or to treat, rescue, or cure muscle disorders, said features or said disorders being linked with muscle contraction, muscle morphology or muscle metabolism.
Owner:CYTOO

Methods of screening for compounds which bind G protein-coupled receptors

The present invention provides a method of screening an agonist or antagonist to a G protein-coupled receptor protein comprising the same or substantially the same amino acid sequence as the amino acid sequence represented by SEQ ID NO: 1, or a salt thereof, which comprises using the receptor protein or a salt thereof and the ligand or a salt thereof; etc. The present invention is useful for screening agents for the prevention / treatment of, e.g., leukopenia, leukemia, lymphoma, malignant tumor, ulcerative colitis, rheumatoid arthritis, inflammatory bowel disorders, tonsil disorders, collagen disease, inflammatory disease, leukocytosis, heart failure, inherited muscle disorders, muscular dystrophy, neuromuscular degenerative disease, myocardial infarction, obesity, mellitus diabetes, hyperlipemia, arteriosclerosis, metabolic syndrome, thrombocytopenia, thrombocytosis, cancer, pulmonary edema, multiple organ failure, etc.
Owner:TAKEDA PHARMA CO LTD

Agents and methods using thereof for the prevention and treatment of stem cell muscle disorders

The present invention relates to agents that induce mitochondrial unfolded protein response (UPR mt) in muscle stem cells and prevents or reverse process of muscle stem cell senescence. Further, the invention relates to methods and compositions useful in the prevention and / or treatment of muscle stem senescence.
Owner:ECOLE POLYTECHNIQUE FEDERALE DE LAUSANNE (EPFL)

Pro-drugs of nsaias with very high skin and membranes penetration rates and their new medicinal uses

InactiveUS20160272653A1Highly preventive effectToxic burdenOrganic active ingredientsNervous disorderSolubilityDISCOID LUPUS ERYTHEMATOSIS
The novel positively charged pro-drugs of NSAIAs in the general formulas (1, 2a, 2b, 2c, or 2d) “Structure 1, 2a, 2b, 2c, or 2d” were designed and synthesized. The compounds of the general formulas (1, 2a, 2b, 2c, or 2d) “Structure 1, 2a, 2b, 2c, or 2d” indicated above can be prepared from metal salts, organic base salts, or immobilized base salts of NSAIAs with suitable halide compounds. The positively charged amino groups in the pro-drugs in this invention largely increase the solubility of the drugs in water and will bond to the negative charge on the phosphate head group of membrane. Thus, the local concentration of the outside of the membrane or skin will be very high and will facilitate the passage of these pro-drugs from a region of high concentration to a region of low concentration. This bonding will disturb the membrane a little bit and may make some room for the lipophilic portion of the pro-drug. When the molecules of membrane move, the membrane may “crack” a little bit due to the bonding of the pro-drug. This will let the pro-drug insert into the membrane. At pH 7.4, only about 99% of the amino group is protonated. When the amino group is not protonated, the bonding between the amino group of the pro-drug and the phosphate head group of the membrane will disassociate, and the pro-drug will enter the membrane completely. When the amino group of the pro-drug flips to the other side of the membrane and thus becomes protonated, then the pro-drug is pulled into the cytosol, a semi-liquid concentrated aqueous solution or suspension. These pro-drugs can be used for treating and preventing diabetes (type I or / and type II), abnormal blood glucose and lipid levels, stroke, heart attack, and other heart and vascular diseases Alzheimer's diseases, Parkinson's diseases and other neurodegenerative diseases, psoriasis, discoid lupus erythematosus, systemic lupus erythematosus (SLE), autoimmune hepatitis, multiple sclerosis (MS), and other autoimmune diseases, amyotrophic lateral sclerosis (ALS), oculopharyngeal muscular dystrophy (OPMD), and other muscle disorders, inflamed hemorrhoids, cryptitis, other inflammatory conditions of the anorectum, and pruritus ani, prostatitis, prostatocystitis, varicose veins, autoimmune liver inflammation, autoimmune kidney inflammation, vein inflammation and other inflammations, skin cancers, breast cancer, colon-rectum cancer, oral cancer, and other cancers, scars, abnormal vascular skin lesions, birthmarks, moles (nevi), skin tags, aging spots (liver spots), and other skin disorders. These pro-drugs can be administered transdermally without the help of skin penetration enhancers.
Owner:TECHFIELDS BIOCHEM CO LTD

Unit for action on biologically active body points and the relief of paravertebral muscles

A unit has been designed to be applied within the area of physiotherapy and is applicable to both medical and athletic therapeutic programs to provide correction of functional states of the spine and the nervous system to eliminate nervous overloads, fatigue, and stress. Moreover, the unit corrects spinal disorders, paravertebral muscular disorders and can be used as a part of mobilizing procedures to act on biologically active body points, and as a part of therapeutic procedures to relieve the spine.
Owner:YARA LLC

Prescription algorithm-based intermediate-frequency swallowing dysfunction treatment method

A Prescription Algorithm-Based Treatment for IF Swallowing Dysfunction. According to the patient's condition and doctor's diagnosis, the treatment is divided into six prescriptions, which are: prescription 1, disuse muscle atrophy dysphagia; prescription 2, pseudobulbar palsy swallowing muscle disorder; prescription 3, bulbar paralysis swallowing muscle disorder; prescription 4 : Prevention of disuse atrophy of swallowing muscles; Prescription 5: Mild swallowing dysfunction; Prescription 6: Painful swallowing. For different prescriptions, six different sub-prescription algorithms are executed through the transfer procedure. Through this algorithm, patients with swallowing dysfunction can be treated intelligently.
Owner:CHINESE PEOPLE'S PUBLIC SECURITY UNIVERSITY +2

Method of treating wound by phycotoxins

InactiveCN1993089AProsthesisGastroparesisBladder Spasm
Pharmaceutical compositions comprising tricyclic 3,4-propinoperhydropurines and uses thereof for treating wounds, anal fissure, achalasia, disorders of the upper and lower esophageal sphincter, gastroparesis, hypertrophic pyloric stenosis, hemorrhoids, proctalgia fugax, irritable bowel syndrome, muscular spasms, vasospastic disorders, disorders involving uterine, or bladder spasm, sphincter of Oddi dysfunction, and short-segment Hirschprung's are provided. Also provided are methods of treating wounds and muscle disorders by administering the composition of the invention to a muscle or in the vicinity of a muscle either topically or by injection.
Owner:PHYTOTOX LTD

Composition containing ornithine and/or aspartic acid and use thereof

Methods and compositions comprising ornithine and / or aspartate that are useful for lowering one or more hyperlipidemic risk factor levels are described. More specifically, compositions comprising ornithine and / or aspartate that are useful for lowering lipid and / or lipoprotein levels, such as triglyceride, cholesterol and LDL levels, in the bloodstream in a subject are described. Methods of using compositions comprising ornithine and / or aspartate for ameliorating the side-effect induced by a therapeutic agent (e.g., statin) or a condition that is associated with an elevation of CPK (e.g., rhabdomyolysis or myopathy) are also described.
Owner:WUHAN QR PHARMA CO LTD

Compositions and methods using combination of calcium and at least one of oleuropein or metabolite thereof

A combination of calcium and at least one of oleuropein or metabolite thereof can be orally administered to an individual in an amount effective to achieve at least one result that is (i) improved mitochondrial calcium uptake in muscle cells, (ii) improved utilization of calcium in muscle cells, (iii) increased mitochondrial energy in muscle cells, (iv) improvement in at least one of muscle functionality, muscle performance, or muscle strength, (v) decreased muscle fatigue, (vi) increased mobility, and / or (vii) treatment of a muscle disorder linked to calcium depletion or deficiency. The individual can be at least one of an aging subject; an elderly subject; a subject with muscle fatigue or muscle weakness; a subject with impaired mobility; a frail subject; a pre-frail subject; a sarcopenic subject; a subject recovering from pre-frailty, frailty, sarcopenia or impaired mobility; a subject undergoing physical rehabilitation; a sportsman; or a pet.
Owner:SOC DES PROD NESTLE SA
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Patsnap Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More
PatSnap group products